window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 19, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

genomics

  • Drug Discovery & Development,Genomics and sequencing,Research & Development

    NEB launches cell-free RNA extraction kit for liquid biopsy research Slug: neb-c

    New England Biolabs has launched a magnetic bead-based extraction kit [...]

    August 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Genomics and sequencing,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Medicus Pharma gets UAE approval to start genomics-guided endometriosis study

    Medicus Pharma has received authorisation from the UAE Department of [...]

    July 31, 2026
  • Genomics and sequencing,Research & Development

    Novogene expands single-cell sequencing capability in Cambridge

    Novogene Europe has expanded its single-cell RNA sequencing capability at [...]

    July 27, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain,Medical devices,Research & Development

    Pioneer launches regional accelerator programmes for life science and tech start-ups

    Pioneer Group has launched regional accelerator programmes in Cambridge and [...]

    July 24, 2026
  • Clinical & Regulatory,Digital & Data,Genomics and sequencing,Research & Development

    Seegene launches global study to evaluate comprehensive PCR testing for respiratory infections

    Seegene has launched the Global Million Clinical Study (GMCS), an [...]

    July 16, 2026
  • Drug Discovery & Development,Genomics and sequencing,Research & Development

    Novogene expands Cambridge Omics Centre with untargeted metabolomics service

    Novogene Europe has expanded its Cambridge Omics Centre with the [...]

    July 14, 2026
  • Digital & Data,Genomics and sequencing

    Wellcome Genome Campus expands AI and genomics ambitions with new advisory group

    The Wellcome Genome Campus has established a Science and Technology [...]

    June 18, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Medicus files IND for genomics-enabled Phase 2 endometriosis trial

    Medicus Pharma has submitted an investigational new drug application in [...]

    June 11, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Genomics and sequencing

    10x Genomics acquires Proteintech Genomics to expand single-cell proteomics capabilities

    10x Genomics has acquired Proteintech Genomics, a division within Proteintech [...]

    June 10, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    Primerdesign and Origin partner on rectal mucus DNA extraction for colorectal cancer detection

    Primerdesign and Origin Sciences partner to develop a DNA extraction [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • CN Bio wins Innovate UK grant to develop human-relevant drug testing workflow
    Categories: Digital & Data, Drug Discovery & Development, Manufacturing & Supply Chain, Research & Development
  • FDA grants Priority Review to Belite Bio’s tinlarebant for Stargardt disease
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Skylark Bio doses first patient in Phase 1/2 trial for GJB2-related deafness
    Categories: Advanced Therapies, Clinical & Regulatory, Genomics and sequencing, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top